Takahisa Takino Selected Research

Matrix Metalloproteinase 14 (MT1-MMP)

9/2021	TGF-β1 facilitates MT1-MMP-mediated proMMP-9 activation and invasion in oral squamous cell carcinoma cells.
8/2016	miR-150-5p and miR-133a suppress glioma cell proliferation and migration through targeting membrane-type-1 matrix metalloproteinase.
1/2016	Tip60 regulates MT1-MMP transcription and invasion of glioblastoma cells through NF-κB pathway.
12/2014	Vinculin negatively regulates transcription of MT1-MMP through MEK/ERK pathway.
7/2013	MT1-MMP prevents growth inhibition by three dimensional fibronectin matrix.
11/2011	Membrane-type 1 matrix metalloproteinase regulates fibronectin assembly to promote cell motility.
11/2010	GI24 enhances tumor invasiveness by regulating cell surface membrane-type 1 matrix metalloproteinase.
6/2010	MT1-MMP promotes cell growth and ERK activation through c-Src and paxillin in three-dimensional collagen matrix.
4/2010	Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion.
11/2008	Activation of matrix metalloproteinase-2 (MMP-2) by membrane type 1 matrix metalloproteinase through an artificial receptor for proMMP-2 generates active MMP-2.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takahisa Takino Research Topics

Disease

27	Neoplasms (Cancer) 09/2021 - 05/2003
10	Neoplasm Metastasis (Metastasis) 01/2021 - 07/2003
5	Fibrosarcoma 07/2013 - 10/2003
4	Glioma (Gliomas) 08/2016 - 11/2008
3	Glioblastoma (Glioblastoma Multiforme) 01/2016 - 05/2003
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 12/2014 - 11/2010
2	Squamous Cell Carcinoma of Head and Neck 09/2021 - 09/2021
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 01/2013
2	Pathologic Processes 01/2021 - 01/2020
2	Brain Neoplasms (Brain Tumor) 01/2016 - 11/2005
2	Breast Neoplasms (Breast Cancer) 11/2011 - 01/2009
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Hypoxia (Hypoxemia) 01/2017
1	Colonic Neoplasms (Colon Cancer) 10/2004
1	Lymphatic Metastasis 10/2004
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 10/2004
1	Bronchiolitis Obliterans Syndrome 02/2004
1	Fibrosis (Cirrhosis) 02/2004
1	Lung Diseases (Lung Disease) 02/2004

Drug/Important Bio-Agent (IBA)

16	Matrix Metalloproteinase 14 (MT1-MMP)IBA 09/2021 - 10/2003
6	Matrix Metalloproteinases (MMPs)IBA 09/2021 - 02/2004
5	Messenger RNA (mRNA)IBA 08/2016 - 05/2003
5	CollagenIBA 11/2012 - 12/2007
3	pro-matrix metalloproteinase 9IBA 09/2021 - 03/2017
3	Phosphotransferases (Kinase)IBA 12/2013 - 02/2004
3	Fibronectins (Fibronectin)IBA 07/2013 - 01/2009
3	Peptide Hydrolases (Proteases)FDA Link 03/2012 - 11/2008
3	Proteins (Proteins, Gene)FDA Link 03/2012 - 05/2003
3	Matrix Metalloproteinase 1 (Interstitial Collagenase)IBA 04/2010 - 10/2004
2	Collagenases (Collagenase)FDA Link 09/2021 - 02/2004
2	Celecoxib (Celebrex)FDA Link 01/2021 - 01/2020
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2020
2	Glycogen Synthase KinasesIBA 02/2015 - 01/2013
2	Focal Adhesion Protein-Tyrosine KinasesIBA 02/2015 - 06/2010
2	LigandsIBA 12/2013 - 07/2003
2	Tyrosine (L-Tyrosine)FDA Link 12/2013 - 05/2003
2	Small Interfering RNA (siRNA)IBA 11/2010 - 06/2010
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 06/2010 - 11/2008
2	Collagen Type IV (Type IV Collagen)IBA 01/2009 - 02/2004
2	EnzymesIBA 10/2004 - 02/2004
2	Complementary DNA (cDNA)IBA 10/2004 - 10/2003
1	Transforming Growth Factors (Transforming Growth Factor)IBA 09/2021
1	GelatinasesIBA 09/2021
1	Histones (Histone)IBA 01/2021
1	Lysine (L-Lysine)FDA Link 01/2021
1	Biological ProductsIBA 01/2021
1	MethyltransferasesIBA 01/2020
1	Transforming Growth Factor beta (TGF-beta)IBA 01/2020
1	N-methyladenosineIBA 01/2020
1	6-methyladenineIBA 01/2020
1	Tissue Inhibitor of Metalloproteinase-1IBA 03/2017
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2017
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2017
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2017
1	NF-kappa B (NF-kB)IBA 01/2016
1	JNK Mitogen-Activated Protein KinasesIBA 02/2015
1	Temozolomide (Temodar)FDA LinkGeneric 02/2015
1	Glycogen Synthase (Synthase I)IBA 02/2015
1	VinculinIBA 12/2014
1	EphrinsIBA 12/2013
1	EphA1 Receptor (Eph Receptor)IBA 12/2013
1	Gemcitabine FDA Link 01/2013
1	matriptaseIBA 03/2012
1	Dexamethasone (Maxidex)FDA LinkGeneric 11/2011
1	Matrix Metalloproteinase InhibitorsIBA 06/2010
1	PaxillinIBA 06/2010
1	Collagen Type I (Type I Collagen)IBA 04/2010
1	GelatinIBA 04/2010
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 04/2010
1	Cadherins (E-Cadherin)IBA 01/2009
1	Cathepsin GIBA 01/2009
1	Tissue Inhibitor of Metalloproteinase-2IBA 11/2008
1	Growth Differentiation Factor 15IBA 09/2007
1	Metalloproteases (Metalloproteinases)IBA 09/2007
1	progelatinaseIBA 04/2005
1	DNA (Deoxyribonucleic Acid)IBA 10/2004
1	Thymidine PhosphorylaseIBA 10/2004
1	Capecitabine (Xeloda)FDA Link 10/2004
1	Green Fluorescent ProteinsIBA 10/2004
1	AgarIBA 10/2004
1	Proteoglycans (Proteoglycan)IBA 10/2004
1	LumicanIBA 10/2004
1	Mitogen-Activated Protein KinasesIBA 02/2004
1	Enzyme Precursors (Zymogens)IBA 02/2004
1	Syndecan-1 (Syndecan 1)IBA 10/2003
1	Peptides (Polypeptides)IBA 07/2003
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 07/2003
1	KisspeptinsIBA 07/2003
1	Crk-Associated Substrate ProteinIBA 05/2003

Therapy/Procedure

3	Therapeutics 08/2016 - 01/2013
1	Radiotherapy 01/2013
1	Lung Transplantation 02/2004